Redeye comments on the news that Bioservo has initiated the process of liquidation.
Redeye saw sales that were in line with our expectations.
Redeye comments on the better-indicated momentum for Carbonhand in Germany.
Redeye comments on today’s news that Bioservo is exploring alternatives to accelerate commercialization by appointing a committee to look in...
Redeye saw sales that were considerably lower than our expectations.
Redeye comments on the wholesale distributor agreement in the US with VHSS.
Redeye resumes its coverage of Bioservo Technologies following the completion of the rights issue, adding SEK 37m before transaction cost.
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Redeye saw results that did not represent a significant deviation from the expectations.
Redeye saw sales roughly in line with our expectations in the Q1 report, as deliveries of Carbonhand were made in the quarter.
Redeye is positive that Bioservo has registered Carbonhand as a medical-technical product according to the 510(k) exemption.
Redeye is viewing the progress in bringing Carbonhand to the market as encouraging.
Redeye saw no breakthrough in sales in Q4, and costs were higher than expected.
Redeye saw sales lower than our expectations in the Q4 report partly due to the delays for Carbonhand in the quarter.
Redeye is encouraged by the positive results at the Waupaca Foundry, where both the employees are satisfied, and incident reports show incid...
Redeye comments on the first deliveries of the new Carbonhand to patients and is happy to see a good start for the Carbonhand launch.
Redeye reduces our short-term lower estimated number of systems to be sold during 2022e and, to an extent, in 2023e.
Redeye is pleased that Bioservo’s Carbonhand 2.0 has now been classified and approved as a medical device according to the MDR, thus opening...
Redeye comments on the strong initial news flow around the launch of the new Carbonhand.
Redeye is positive regarding the news that Bioservo is now launching the long-awaited next generation of Carbonhand.
Redeye reduces our short-to mid-term estimates due to a lower estimated number of systems to be sold during 2023E and, to an extent, into 20...
Redeye has a positive view of the new distribution agreement for Carbonhand in Switzerland.
Redeye has a positive view of the preliminary results from the ongoing iHand study presented at the IFSSH & IFSHT in London.
Redeye adjusts the short-term estimates downward due to a slightly more challenging business environment.
Redeye's first impressions on the Q1 report from Bioservo earlier this morning.
Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view.
Redeye's first impressions on the Q4 report from Bioservo earlier this morning.
Redeye initiates coverage of Bioservo Technologies, a Swedish technology, and medical technology company.
